
Oral direct-acting antivirals (DAAs) demonstrated high efficacy and safety in HCV-infected children, even with comorbidities. A study of 187 children (61% with comorbidities) showed a 98.9% cure rate with sofosbuvir/ledipasvir. Mild side effects like headache and irritability were transient, ensuring uninterrupted treatment.
Like
Save
Share